JAGUAR HEALTH, INC. Increase (Decrease) in Royalties Payable
JAGUAR HEALTH, INC. (JAGX) reported Increase (Decrease) in Royalties Payable of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRoyaltiesPayable · last filed 2020-11-16
- 2020-09-30: Increase (Decrease) in Royalties Payable 9 month $0.00.
| Period end | Increase (Decrease) in Royalties Payable 9 month |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |